VGI Health Technology Limited

NSX:VTL ISIN:AU0000152597

Azure Health Technology LimitedVGI Health Technology Limited (NSX:VTL) is an Australian public listed biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

  

News

VGI Health Technology Limited (NSX:VTL) FY21 Annual Report issued to Shareholders

🕔9/22/2021 10:36:00 AM 989

VGI Health Technology Limited (NSX:VTL) is pleased to present the FY21 Annual Report to Shareholders.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Appointment of Professor Crawford to SAB

🕔9/15/2021 10:12:00 AM 1253

VGI Health Technology Limited (NSX:VTL) is pleased to announce that eminent hepatologist, Professor Darrell H.G. Crawford, has been appointed to its Scientific Advisory Board (SAB).

Read Full Article

VGI Health Technology Limited (NSX:VTL) Appointment of Clinical Study Site

🕔9/14/2021 9:56:00 AM 1272

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd, has appointed Gallipoli Medical Research Foundation (GMRF) as a clinical study site for Phase II Clinical Study.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Study Protocol Approved

🕔9/13/2021 9:39:00 AM 1540

VGI Health Technology Limited (NSX:VTL) is pleased to announce that it's operational subsidiary, Invictus Ops Pty Ltd., has approved a clinical study protocol for a clinical study to be conducted by Altipure R&D in Ohio.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Renewal of Research and Development Receivable Facility

🕔9/7/2021 9:12:00 AM 1402

VGI Health Technology Limited (NSX:VTL) is pleased to announce that it has agreed with FIFO Capital to renew a Receivable Finance Facility with respect to VTL's assessed tax cash benefit under the Federal Government's R&D Tax Incentive Program.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Certification of NE1-Elite(R)

🕔8/12/2021 9:30:00 AM 1593

Invictus Nutraceuticals, Inc. (Florida, USA), a wholly owned subsidiary of VGI Health Technology Limited (NSX:VTL), is pleased to announce that it has partnered with Informed Sport to certify its NE1-Elite(R) product.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Shareholder Update

🕔7/13/2021 1:09:00 PM 1909

VGI Health Technology Limited (NSX:VTL) recently signed a manufacturing and supply agreement with a US manufacturer, Altipure LLC, for finished nutraceutical products for sale and clinical study drugs for our clinical studies.

Read Full Article

Azure Health Technology Limited (NSX:VTL) Receipt of Finished Nutraceutical Products

🕔6/15/2021 9:49:00 AM 2004

Further to Azure Health Technology Limited's (NSX:VTL) announcement on 16 March 2021 that the first manufacturing run for our finished nutraceutical products has been completed.

Read Full Article

Azure Health Technology Limited (NSX:VTL) Initiation Report

🕔6/8/2021 7:28:00 AM 1833

Azure Health Technology Limited (NSX:VTL) trading as VGI Health Technology is pleased to announce that Pitt Street Research has issued an Initiation Report.

Read Full Article

Azure Health Technology Limited (NSX:VTL) Appointment of cGMP Manufacturer

🕔6/7/2021 9:10:00 AM 2014

Azure Health Technology Limited trading as VGI Health Technology (NSX:VTL) is pleased to announce that an additional current Good Manufacturing Practice (cGMP) manufacturer has been appointed in the US.

Read Full Article
###

2,828 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 352) (Last 30 Days: 1145) (Since Published: 2828) 

Company Data

    Headquarters
  • Level 45, Suite 03
    19-29 Martin Place
    Sydney, NSW, 2003
    Australia
  • Telephone
  • +61-2-8279-8908 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Healthcare 
  • Homepage
  • www.vgiht.com

Company Reports

Quarterly Report

Social Media